As Conatus Pharmaceuticals (CNAT) Stock Value Rose, Mpm Asset Management Has Upped Its Holding; Icm Asset Management Boosted Kratos Defense & Security Solu (KTOS) Holding by $322,820; Shares Declined

May 1, 2018 - By Marguerite Chambers

Icm Asset Management Inc increased its stake in Kratos Defense & Security Solu (KTOS) by 12.02% based on its latest 2017Q4 regulatory filing with the SEC. Icm Asset Management Inc bought 32,282 shares as the company’s stock declined 12.63% with the market. The institutional investor held 300,770 shares of the capital goods company at the end of 2017Q4, valued at $3.19M, up from 268,488 at the end of the previous reported quarter. Icm Asset Management Inc who had been investing in Kratos Defense & Security Solu for a number of months, seems to be bullish on the $1.04 billion market cap company. The stock decreased 3.93% or $0.41 during the last trading session, reaching $10.01. About 1.49M shares traded. Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) has risen 19.52% since May 1, 2017 and is uptrending. It has outperformed by 7.97% the S&P500.

Mpm Asset Management Llc increased its stake in Conatus Pharmaceuticals Inc. (CNAT) by 76.26% based on its latest 2017Q4 regulatory filing with the SEC. Mpm Asset Management Llc bought 909,091 shares as the company’s stock rose 13.83% while stock markets declined. The institutional investor held 2.10 million shares of the major pharmaceuticals company at the end of 2017Q4, valued at $9.71M, up from 1.19M at the end of the previous reported quarter. Mpm Asset Management Llc who had been investing in Conatus Pharmaceuticals Inc. for a number of months, seems to be bullish on the $102.51 million market cap company. The stock decreased 0.87% or $0.03 during the last trading session, reaching $3.41. About 383,704 shares traded. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has risen 12.92% since May 1, 2017 and is uptrending. It has outperformed by 1.37% the S&P500.

Among 7 analysts covering Conatus Pharma (NASDAQ:CNAT), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conatus Pharma had 16 analyst reports since September 22, 2015 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $1800 target in Thursday, June 29 report. The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) earned “Buy” rating by Stifel Nicolaus on Thursday, November 5. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 22. The firm earned “Buy” rating on Thursday, March 1 by Oppenheimer. The stock has “Buy” rating by H.C. Wainwright on Thursday, April 5. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, December 20 report. The firm earned “Buy” rating on Friday, July 1 by Roth Capital. The firm earned “Buy” rating on Wednesday, November 9 by Stifel Nicolaus. Oppenheimer maintained Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) on Wednesday, March 7 with “Buy” rating. The rating was maintained by Stifel Nicolaus on Thursday, August 3 with “Buy”.

Investors sentiment decreased to 1.1 in Q4 2017. Its down 0.73, from 1.83 in 2017Q3. It turned negative, as 14 investors sold CNAT shares while 17 reduced holdings. 11 funds opened positions while 23 raised stakes. 11.71 million shares or 7.58% more from 10.89 million shares in 2017Q3 were reported. Courage Mgmt Limited Liability Company reported 200,000 shares. Strs Ohio reported 26,700 shares. Mpm Asset Limited Liability Corporation accumulated 2.10M shares or 3.89% of the stock. Schwab Charles Mngmt holds 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 180,556 shares. Panagora Asset Mngmt owns 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 152,975 shares. Rhumbline Advisers reported 22,520 shares. Northern Tru Corp holds 285,401 shares or 0% of its portfolio. Barclays Plc reported 4,170 shares stake. California State Teachers Retirement has 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Citigroup reported 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Moreover, Architects Inc has 0% invested in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Goldman Sachs Grp Inc holds 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 73,751 shares. Fincl Bank Of Montreal Can has 23,614 shares. Tiaa Cref Investment Mgmt Lc holds 216,766 shares or 0% of its portfolio. Tci Wealth Advisors holds 0% or 10 shares in its portfolio.

Investors sentiment decreased to 1.68 in Q4 2017. Its down 0.08, from 1.76 in 2017Q3. It turned negative, as 26 investors sold KTOS shares while 27 reduced holdings. 37 funds opened positions while 52 raised stakes. 60.62 million shares or 6.85% more from 56.73 million shares in 2017Q3 were reported. Vanguard Group Inc owns 3.83 million shares or 0% of their US portfolio. Voya Invest Mngmt Ltd Co holds 33,628 shares. Nuveen Asset Mgmt Limited Liability accumulated 297,268 shares or 0.02% of the stock. Rhumbline Advisers reported 0% of its portfolio in Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS). Advisory holds 62,498 shares or 0.01% of its portfolio. Geode Capital Management Lc holds 776,737 shares. Macquarie Group Incorporated Limited accumulated 136,463 shares. Wells Fargo & Mn invested in 0% or 125,727 shares. Driehaus Capital Management Ltd Liability Com invested in 406,286 shares. 75,100 are owned by Glacier Peak Capital Lc. Icm Asset Management Wa owns 300,770 shares. Public Employees Retirement Association Of Colorado holds 0% of its portfolio in Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) for 3,154 shares. 1,721 were accumulated by Parkside Commercial Bank &. Emerald Advisers Pa holds 2.30 million shares or 0.94% of its portfolio. Millennium Mgmt Ltd owns 0.04% invested in Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) for 2.52 million shares.

Since March 5, 2018, it had 4 insider purchases, and 0 insider sales for $184,962 activity. 3,205 shares were bought by Zegart Amy, worth $34,993 on Tuesday, March 6. Another trade for 4,000 shares valued at $37,802 was bought by Carrai Phillip D. Shares for $11,887 were bought by Judd Jane Elizabeth on Monday, March 5.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>